The CFDA may soon have a plan for expedited IND approvals that would render a decision within 60 days. That would be a big change. Currently, companies must wait one to two years (or longer) before the agency rules on whether they can begin China clinical trials of a new drug. Several Asian countries -- Taiwan, Singapore and South Korea -- already have expedited approvals. China is drawing up plans for a pilot program for use with oncology drugs. Presumably, it will be put to wider use if the program works.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
